1.

81例挽救性治疗的Ⅳ期肺腺癌患者靶向药物治疗失败后生存时间的单因素及多因素分析

Single-factor and multivariate analysis of follow up time for 81 phase IV lung adenocarcinoma patients receiving salvage therapy

Variable	n	Median follow up time (month)	Single-factor analysis			Multivariate analysis
			χ2	P		HR	95%CI	P
PS: performance status; PFS: progression free survival
Gender			1.228	0.268		1.530	0.652-3.601	0.388
Male	38	8.8
Female	43	9.9
Age (year)			0.003	0.956		1.040	0.530-2.042	0.651
< 60	43	9.9
≥60	38	9.0
Smoking history			3.136	0.077		1.418	0.512-3.923	0.097
Yes	32	8.8
No	49	9.9
ECOG PS score			36.500	0.001		0.180	0.060-0.250	< 0.01
0-1	42	14.6
2	39	5.0
Surgery history			2.888	0.089		0.738	0.314-1.737	0.218
Yes	32	12.8
No	49	8.8
Radiotherapy history			1.147	0.284		1.473	0.754-2.879	0.116
Yes	39	8.8
No	42	12.0
Situation of metastasis			4.100	0.041		0.490	0.280-0.870	0.020
One	36	13.8
More than one	45	8.6
PFS with EGFR-TKIs (month)			1.565	0.211		0.772	0.407-1.466	0.078
< 6	40	10.0
≥6	41	7.9
Progression situation of TKIs therapy			0.021	0.884		1.589	0.763-3.311	0.884
Enlargement of primary lesion	42	8.8
New lesion of metastasis	39	9.5
Plural effusion of post-TKIs therapy			5.293	0.021		0.540	0.310-0.980	0.030
None or less	49	11.9
Median or large	32	7.3
CEA value of post-target therapy			0.508	0.476		1.588	0.778-3.241	0.407
Normal	29	10.6
Abnormal	34	9.0
Salvage therapy			0.162	0.688		0.998	0.517-1.982	0.278
Pemetrexed alone	46	7.7
Combined with oxaliplatin	35	10.0